Global Assets Advisory LLC Has $851,000 Stock Holdings in Amgen Inc. $AMGN

Global Assets Advisory LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,930 shares of the medical research company’s stock after acquiring an additional 155 shares during the quarter. Global Assets Advisory LLC’s holdings in Amgen were worth $851,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC increased its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Impact Capital Partners LLC boosted its stake in Amgen by 4.3% in the 1st quarter. Impact Capital Partners LLC now owns 937 shares of the medical research company’s stock worth $292,000 after purchasing an additional 39 shares during the period. Congress Asset Management Co. grew its position in Amgen by 0.8% during the 1st quarter. Congress Asset Management Co. now owns 62,909 shares of the medical research company’s stock worth $19,599,000 after purchasing an additional 473 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Amgen by 4.5% in the first quarter. Sivia Capital Partners LLC now owns 1,072 shares of the medical research company’s stock valued at $334,000 after purchasing an additional 46 shares in the last quarter. Finally, Perennial Advisors LLC boosted its position in shares of Amgen by 2.8% in the first quarter. Perennial Advisors LLC now owns 19,671 shares of the medical research company’s stock worth $6,128,000 after buying an additional 530 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.2%

NASDAQ AMGN opened at $297.89 on Monday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The stock has a market cap of $160.37 billion, a PE ratio of 24.36, a PEG ratio of 2.59 and a beta of 0.49. The firm has a 50-day simple moving average of $287.34 and a 200 day simple moving average of $287.98. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is 77.84%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AMGN. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday. Citigroup lifted their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Finally, Morgan Stanley boosted their price target on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $309.70.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.